The expression profile of angiogenic genes in critical limb ischemia popliteal arteries

Critical limb ischemia (cli) represents the most severe form of peripheral arterial disease (pad) and is the leading cause of non-traumatic amputations in western populations. in recent years,therapeutic angiogenesis has been considered to be a potential treatment option for cli patients,however the molecular mechanism of ischemia-induced vascularization is still not fully understood. the identification of genetic factors underlying vascular responses to ischemia will improve our understanding of the biological causes of the disease and enhance personalized therapies in the future. in this work,we determined,for the first time,the expression profile of angiogenesis-related genes utilizing unique human material: the popliteal arteries retrieved during lower limb amputation from patients with cli. using custom-designed taqman low-density array (tlda) cards we investigated the mrna level of 90 genes on cli samples compared to healthy donors. we identified three significantly up-regulated genes in cli group: matrix metalloproteinase 9 (mmp-9),ve-cadherin (cdh5) and integrin alpha 4 (itga4). however,among all investigated genes,only lymphatic vessel endothelial hyaluronan receptor 1 (lyve1) was significantly reduced. in order to verify whether hypoxic conditions occur in popliteal arteries of cli patients,we validated the transcription level of selected proangiogenic genes by real-time pcr on a larger number of samples. these results showed that the expression of key genes involved in angiogenesis,such as mmp9,hgf,hif1a,vegf-a and flt1 were elevated in patients with cli. moreover,the study revealed that the expression of vegf-a and flt1 was associated with activation of hif1a transcription. in conclusion,our data revealed the alteration in the mrna level of genes involved in matrix remodelling,cell-cell adhesion as well as endothelial cell migration and proliferation in human popliteal arteries. © 2016,polish physiological society. all rights reserved.